Skip to content

Multicenter Research on Microwave Ablation Combined with 125I Seed Implantation for Advanced Tumors

Multicenter Research on Microwave Ablation Combined with 125I Seed Implantation for Advanced Tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107807
Enrollment
Unknown
Registered
2025-08-19
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer

Interventions

Test group:Ultrasound-guided Microwave Ablation combined with 125Iodine (125I) Particle Implantation

Sponsors

Affiliated Hospital of Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Primary liver cancer: solitary tumor with diameter <=5 cm; or multiple tumors (number <=3) with the largest diameter <=3 cm. (2) Liver metastases: the primary lesion has been effectively controlled, with no extrahepatic metastases or stable extrahepatic metastatic foci, and intrahepatic lesions are expected to be completely ablated. (3) Superficial tumors: systemic superficial metastatic tumors or primary superficial tumors. (4) Palliative treatment for advanced tumors, aiming to maximally reduce tumor burden, alleviate tumor-related symptoms, improve patients' quality of life, and prolong survival.

Exclusion criteria

Exclusion criteria: (1) Diffuse tumor distribution. (2) Invasion of adjacent hollow organs. (3) Liver function Child-Pugh class C. (4) Uncorrectable coagulation dysfunction. (5) Concurrent active infection, especially biliary tract infection. (6) Refractory massive ascites or cachexia. (7) Failure of vital organs (heart, brain, lungs, kidneys). (8) ECOG performance status > grade 2. (9) Impaired consciousness or inability to cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
overall survival;progress free survival;time to tumor progression;

Secondary

MeasureTime frame
Clinical Symptom Improvement and Quality of Life Assessment;The comprehensive evaluation was conducted using the Quality of Life Assessment Scale combined with pain scores and performance status scores;Tumor Marker;Lymphocyte Subsets;TNF-a;

Countries

China

Contacts

Public ContactChen Baoding

Affiliated Hospital of Jiangsu University

alphalife@163.com+86 135 1169 6205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026